Arcellx [ACLX] vs Regeneron [REGN] Detailed Stock Comparison

Arcellx Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Arcellx Inc. wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 15 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Arcellx Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 16.56 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 12.90 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -66.41 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -25.69 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -3,850.24% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -53.42% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -24.05% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-212.59M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 95.76% 15.66% Arcellx Inc.
Price-to-Sales Ratio (TTM) 301.85 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $6.33B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 284.02 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-4.07 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.25 0.40 Arcellx Inc.
Short % of Float 5.27% 2.55% Regeneron Pharmaceuticals, Inc.

Arcellx Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

ACLX
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcellx Inc.0.00%0.00%0.06%63.92%27.37%81.67%
Regeneron Pharmaceuticals, Inc.0.46%0.60%-11.93%-18.75%-18.29%-20.78%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcellx Inc.95.76%177.88%584.94%584.94%584.94%584.94%
Regeneron Pharmaceuticals, Inc.15.66%-21.83%13.80%72.82%1,033.17%4,804.97%

Performance & Financial Health Analysis: Arcellx Inc. vs Regeneron Pharmaceuticals, Inc.

MetricACLXREGN
Market Information
Market Cap i$6.73B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i616,459642,495
90 Day Avg. Volume i1,025,300617,765
Last Close$115.07$614.98
52 Week Range$56.58 - $115.13$503.25 - $821.11
% from 52W High-0.05%-25.10%
All-Time High$115.13 (Apr 17, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-0.05%-49.23%
Growth Metrics
Quarterly Revenue Growth-0.89%0.03%
Quarterly Earnings Growth-0.89%-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i-38.50%0.23%
Return on Equity (TTM) i-0.53%0.15%
Debt to Equity (MRQ) i12.909.51
Cash & Liquidity
Book Value per Share (MRQ)$6.95$304.65
Cash per Share (MRQ)$7.70$83.86
Operating Cash Flow (TTM) i$-210,258,000$4.98B
Levered Free Cash Flow (TTM) i$-97,093,872$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Arcellx Inc. vs Regeneron Pharmaceuticals, Inc.

MetricACLX (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-66.4114.21
PEG Ratio i-66.41-4.80
Price to Sales (TTM) i301.855.50
Price to Book (MRQ) i16.562.45
Market Capitalization
Market Capitalization i$6.73B$80.98B
Enterprise Value i$6.33B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i284.024.95
Enterprise to EBITDA i-25.6916.72
Risk & Other Metrics
Beta i0.250.40
Book Value per Share (MRQ) i$6.95$304.65

Financial Statements Comparison: Arcellx Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricACLX (2025)REGN (2025)
Revenue/Sales i22.29M14.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i0.0%14.6%
Gross Profit iN/A12.24B
Gross Margin i0.0%85.4%
Research & Development i157.61M5.85B
Operating Income (EBIT) i-253.08M3.70B
Operating Margin i-1,135.6%25.8%
EBITDA i-222.19M5.00B
EBITDA Margin i-997.0%34.8%
Pre-Tax Income i-228.87M5.23B
Pre-Tax Income % of Revenue i-1,026.9%36.5%
Income Tax i69,000725.80M
Income Tax % of Revenue i0.3%5.1%
Net Income (Profit) i-228.93M4.50B
Profit Margin i-1,027.3%31.4%

Balance Sheet & Liquidity Metrics

MetricACLX (2025)REGN (2025)
Cash & Equivalents i80.26M3.12B
Total Current Assets i462.18M18.02B
Total Current Assets % of Revenue i2,073.9%125.7%
Total Current Liabilities i104.20M4.37B
Total Current Liabilities % of Revenue i467.6%30.5%
Long-Term Debt i44.34M2.71B
Long-Term Debt % of Revenue i199.0%18.9%
Total Shareholders Equity i402.35M31.26B
Retained Earnings i-725.76M35.80B
Retained Earnings % of Revenue i-3,256.6%249.6%
Property, Plant & Equipment i42.63M1.54B

Cash Flow Statement Comparison

MetricACLX (2025)REGN (2025)
Operating Cash Flow i-178.25M6.30B
Operating Cash Flow % of Revenue i-799.8%43.9%
Capital Expenditures i-2.33M0
Free Cash Flow i-212.59M3.77B
FCF Margin i-953.9%26.3%
Debt Repayment i-230,000N/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricACLXREGN
Shares Short i2.27M2.55M
Short Ratio i1.624.46
Short % of Float i5.27%2.55%
Shares Outstanding i57.93M105.72M
Float Shares i42.25M98.55M
% Held by Insiders i12.92%1.98%
% Held by Institutions i90.08%91.08%
% Held by Public i-3.00%6.94%

Dividend Analysis & Yield Comparison: Arcellx Inc. vs Regeneron Pharmaceuticals, Inc.

MetricACLXREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026